Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
This is the ACTIV-2 trial
https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials#activ2
Is this what you are looking for?
https://www.thehindubusinessline.com/news/science/immune-system-protein-inhalation-could-alleviate-covid-19-severity-study/article33100161.ece
A coronavirus mutation could weaken antibodies’ power
A widespread variant of the new coronavirus has the potential to evade the immune response that some people mount after infection.
Since the start of the pandemic, researchers have identified thousands of viral mutations in the genomes of SARS-CoV-2 samples taken from infected people. David Robertson at the University of Glasgow, UK, Gyorgy Snell at Vir Biotechnology in San Francisco, California, and their colleagues examined a mutation called N439K in a protein that the virus uses to invade cells (E. C. Thomson et al. Preprint at bioRxiv https://doi.org/fhnp; 2020).
The mutation affects the protein’s receptor binding domain, which it uses to recognize host cells, and which is a key target of antibodies against the virus. The mutation has emerged independently at least twice and has been identified in 12 countries.
In laboratory experiments, the researchers found that the mutation could hinder the activity of potent neutralizing antibodies that block the virus. Among the neutralizing antibodies that the mutation obstructed were those in the blood of people who had recovered from COVID-19, as well as some manufactured ‘monoclonal antibodies’ that are being developed into treatments.
https://www.nature.com/articles/d41586-020-00502-w
In laboratory experiments, the researchers found that the mutation could hinder the activity of potent neutralizing antibodies that block the virus. Among the neutralizing antibodies that the mutation obstructed were those in the blood of people who had recovered from COVID-19, as well as some manufactured ‘monoclonal antibodies’ that are being developed into treatments.
https://www.asktraders.com/analysis/synairgen-shares-surged-9-44-today-despite-issuing-shares-worth-87m/
''The company’s management has reassured investors that it is working on other drugs to complement its COVID-19 drug and will leverage its enviable market position to generate sales for its other drugs.''
Is this the interview you guys are talking about?
https://www.channel4.com/news/mass-coronavirus-testing-post-lockdown-would-be-way-to-give-people-something-positive-oxford-universitys-sir-john-bell
Reminds me of fundamentals of why I invested and will continue to do so for a very long time. Price is temporary, the quality of the company will shine through eventually.
'As a scientist myself, and son of two medical doctors, I cannot stress enough how important the Intellectual property re: delivery method for therapeutics will be moving forward.
IV is far too expensive for the masses. It is impractical. It is invasive. Uncomfortable. High in toxicity.
Inhalation/Oral/Nasal - This is the way forward. Even IF Foralumab doesn't show true efficacy in the treatment of Covid, then those that can show efficacy (Lily, Regeneron, Gilead, GSK etc etc) will need to use an alternative method to IV to treat the masses for socioeconomic reasons. The patents are worth potentially BILLIONS in licensing fees alone.! assuming they don't sell their IP outright..?
Tiziana is and will be a Monster. Fully expect buy-out offers to come flooding in around Q1 2021.. Average up, average down. Either way. Hold and add in this truly amazing, potentially life changing/saving drugs therapeutics company I am so proud to be a shareholder in.
I want to invest in Placebo as well, they have done so many Clinical Trials with other drugs,
and most of the times Placebo done better in the trials,
but the Clinical Trials with SNG, SNG is 79% better,
I will stick with SNG
Yes, I posted a few day ago,
https://www.synairgen.com/wp-content/uploads/2020/10/Synairgen-FR-presentation-for-Website.pdf
On page 26, SG016 Hospital Phase II Trial
OSCI Score at Baseline (ITT population),
3 = Hospitalised - no oxygen therapy, Placebo: 19 (38%), SNG001: 11 (23%)
4 = Oxygen by mask, or nasal prongs, Placebo: 28 (56%), SNG001: 36 (75%)
5 = Non-invasive ventilation, or highflow oxygen, Placebo: 1 (2%), SNG001: 1 (2%)
Phase II Trial already have 75% scoring a 4 on the WHO scale,
and also have 2% scoring a 5 anyway, I don't think it is to much of a problem.
and from PokerJason, ''They are testing whether double dose is more effective/beneficial, they are trialling new components, they are trialling outcomes across different clinical care settings and different cultures/race.
I hope this happens quick now.''
''Shares are only listed in the UK''
SNG is listed in the US as well, OTCMKTS: SYGGF
https://www.google.com/search?client=opera&q=OTCMKTS%3A%23SYGGF&sourceid=opera&ie=UTF-8&oe=UTF-8
https://www.sharebuyers.co.uk/shares/the-rise-of-covid-stocks-big-likely-winners-revealed/
Synairgen (LON: SNG) – Recently raised £80m to push on with completion of SNG001 – this is a promising treatment that helps treat COVID-19 patients before symptoms get worse in the second week of infection. It could also be used at home and vitally stop COVID-19 progressing to needing hospital treatment. Assuming that COVID-19 is still ravaging on early next year and SNG can bring this to fruition, the size of the opportunity will undoubtedly be huge in a unique space.
''Dave - scoring a 4 on the WHO scale? (this rings a bell)''
On page 26, SG016 Hospital Phase II Trial
OSCI Score at Baseline (ITT population),
3 = Hospitalised - no oxygen therapy, Placebo: 19 (38%), SNG001: 11 (23%)
4 = Oxygen by mask, or nasal prongs, Placebo: 28 (56%), SNG001: 36 (75%)
5 = Non-invasive ventilation, or highflow oxygen, Placebo: 1 (2%), SNG001: 1 (2%)
Phase II Trial already have 75% scoring a 4 on the WHO scale,
and also have 2% scoring a 5 anyway, I don't think it is to much of a problem.
https://www.synairgen.com/wp-content/uploads/2020/10/Synairgen-FR-presentation-for-Website.pdf
A shareholder vote to approve the rights issue will be held on 27 October. Investors will receive their nil paid rights on the ‘ex rights date’ of 28 October providing they haven’t sold their holding before that date.
Don't it means I can't sell today if I want the new shares, but I can sell tomorrow?